Executives at the pharmaceutical company Eli Lilly say they are capping the out-of-pocket cost of insulin to help diabetics during the coronavirus.
They are introducing the Eli Lilly Insulin Value Program, which allows anyone with commercial insurance and those without insurance at all to fill their monthly prescription of Lilly insulin for $35.
The program is now in effect and covers most Lilly insulins.
However, patients with government insurance such as Medicaid, Medicare, Medicare Part D or any State Patient or Pharmaceutical Assistance Program are not eligible for it.
